MiMedx outlines 2027 revenue well in excess of $400M with over 20% adjusted EBITDA margin following planned Sanara deal (NASDAQ:MDXG)
· seekingalpha.com
MiMedx (MDXG) Q2 2026 earnings call: $64M sales, wound stabilization, surgical growth, Sanara acquisition & 2027 synergy targets.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...